Track the LHC Group, Inc stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, LHC Group, Inc has recorded 71 public disclosures. The latest transaction was disclosed on 22 February 2023 (Disposition). Among the most active insiders: Myers Keith G. The full history is openly available.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 71 declarations
LHC Group, Inc. was a U.S.-based provider of post-acute and home-based healthcare services focused on delivering care where patients live. Founded in 1994 in Lafayette, Louisiana, the company began as a single home health agency and expanded over time through organic growth, partnerships, and acquisitions. Its headquarters were in Lafayette, Louisiana, United States. LHC Group traded on the NASDAQ market under the ticker LHCG before being acquired by UnitedHealth Group, with the transaction completed on February 22, 2023. For investors, that history remains relevant in the context of SEC filings, including Form 4 insider transaction reporting. LHC Group’s business model was built around several service lines: home health, hospice, home- and community-based services, facility-based services through long-term acute care hospitals (LTACHs), and healthcare innovations. In practical terms, the company’s economic engine was centered on home-based care, post-discharge clinical follow-up, end-of-life support, and coordination services with hospitals and health systems. Management consistently emphasized a person-centered care approach designed to reduce avoidable readmissions, improve clinical outcomes, and support smoother transitions from acute care to the home setting. From a competitive standpoint, LHC Group established itself as one of the better-known players in the U.S. home health and hospice landscape by combining scale, local market density, and hospital partnership capabilities. Prior to the acquisition, the company reported operating a broad national footprint across most states and the District of Columbia. Its investment case was based on a mix of geographic reach, clinical integration, and the ability to serve an aging population with increasingly complex care needs. The home health and hospice markets are highly fragmented, but they also face reimbursement pressure, regulatory oversight, and a clear industry shift toward value-based care. Its core services included skilled nursing at home, therapy and rehabilitation, assistance with daily living, palliative and hospice care, and broader care-transition support. These offerings made LHC Group particularly relevant for patients recovering from hospitalization, managing chronic conditions, or requiring end-of-life care in a familiar environment. A major recent development is that LHC Group is no longer an independent publicly traded company; it became part of UnitedHealth Group in 2023. That acquisition underscored the strategic value of home-based care assets within the broader U.S. healthcare ecosystem and Optum’s growth strategy. For French-speaking investors, LHC Group is best viewed as a former NASDAQ-listed specialist that helped accelerate consolidation in U.S. home health and hospice care, with a legacy that remains important even after its integration into a larger healthcare platform in the United States.